Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) developer of exoskeletons for use in the healthcare, is expected to report third quarter earnings results, after market close, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.39 per share from revenue of $ 2.45 million.
Looking ahead, the full year loss are expected at $ 2.45 per share on the revenues of $ 9.00 million.
Previous Quarter Performance
Ekso Bionics Holdings, Inc. communicated loss for the second quarter of $ 1.84 per share, from the revenue of $ 2.30 million. The quarterly revenues dropped 29.45 percent compared with the same quarter last year. According to street consensus, EKSO was expected to report 2Q20 loss of $ 0.55 per share from revenue of $ 1.62 million. The bottom line results missed street analysts by $ 1.29 or 234.55 percent, at the same time, top line results outshined analysts by $ 0.68 million or 41.98 percent.
Stock Performance
Shares of Ekso Bionics Holdings, Inc. traded low $ -0.30 or -6.80 percent on Wednesday, reaching $ 4.11 with volume of 108.90 thousand shares. Ekso Bionics Holdings, Inc. has traded high as $ 4.33 and has cracked $ 4.00 on the downward trend
According to the previous trading day, closing price of $ 4.11, representing a 96.00 % increase from the 52 week low of $ 2.25 and a 61.32 % decrease over the 52 week high of $ 11.40.
The company has a market capital of $ 34.18 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Ekso Bionics Holdings, Inc. will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.eksobionics.com
Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments.
